Gaithersburg鈥檚 Novavax Inc. (NASDAQ: NVAX) reported Tuesday positive phase 1 clinical trial data on its COVID-19 vaccine candidate, a necessary step to advance a product officials hope will eventually protect people from coronavirus.
The study found the candidate, called NVX-CoV2373, to both be generally well-tolerated and elicit 鈥渞obust antibody responses,鈥� the company said Tuesday, adding that it showed the potential to reduce the disease鈥檚 transmission.
Specifically, the candidate had a 鈥渞eassuring鈥� safety profile with the most common tenderness and pain at the injection site, and less frequent, systemic symptoms including headache, fatigue and myalgia. And there were no 鈥渟evere鈥� adverse reactions, the company said.
The data demonstrate the candidate has 鈥渁 robust immunogenicity profile,鈥� said Dr. Gregory Glenn, president of research and development for Novavax, in a statement. In addition, he said, it 鈥渆licited neutralizing antibody titers greater than those鈥�
